
Charles B Malpas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7436512/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Reproducibility in the absence of selective reporting: AnÂillustration from largeâ€scale brain asymmetry research. Human Brain Mapping, 2022, 43, 244-254.	1.9	16
2	Time to diagnosis in younger-onset dementia and the impact of a specialist diagnostic service. International Psychogeriatrics, 2022, 34, 367-375.	0.6	38
3	The Diagnostic Challenge of Young-Onset Dementia Syndromes and Primary Psychiatric Diseases: Results From a Retrospective 20-Year Cross-Sectional Study. Journal of Neuropsychiatry and Clinical Neurosciences, 2022, 34, 44-52.	0.9	13
4	Functional connectivity during feedback learning in smokers. Addiction Biology, 2022, 27, e13109.	1.4	2
5	Topographic divergence of atypical cortical asymmetry and atrophy patterns in temporal lobe epilepsy. Brain, 2022, 145, 1285-1298.	3.7	18
6	Plasma neurofilament light chain protein is not increased in treatment-resistant schizophrenia and first-degree relatives. Australian and New Zealand Journal of Psychiatry, 2022, 56, 1295-1305.	1.3	10
7	Cerebrospinal fluid neurofilament light chain differentiates primary psychiatric disorders from rapidly progressive, Alzheimer's disease and frontotemporal disorders in clinical settings. Alzheimer's and Dementia, 2022, 18, 2218-2233.	0.4	24
8	Measuring posttraumatic stress disorder following childbirth. Australasian Psychiatry, 2022, , 103985622210779.	0.4	2
9	Doctor Who? Honorific titles and their influence on patients' perceptions of healthcare professionals. Journal of the Royal Society of Medicine, 2022, 115, 91-94.	1.1	3
10	Multiple Sclerosis Relapses Following Cessation of Fingolimod. Clinical Drug Investigation, 2022, 42, 355-364.	1.1	8
11	Machine learning approaches for imagingâ€based prognostication of the outcome of surgery for mesial temporal lobe epilepsy. Epilepsia, 2022, 63, 1081-1092.	2.6	10
12	Multiple Sclerosis Severity Score (MSSS) improves the accuracy of individualized prediction in MS. Multiple Sclerosis Journal, 2022, , 135245852210845.	1.4	2
13	The dynamics of relapses during treatment switch in relapsing-remitting multiple sclerosis. Journal of Theoretical Biology, 2022, 541, 111091.	0.8	2
14	Association of Latitude and Exposure to Ultraviolet B Radiation With Severity of Multiple Sclerosis. Neurology, 2022, 98, .	1.5	12
15	Psychometric deficits in autoimmune encephalitis: A retrospective study from the Australian Autoimmune Encephalitis Consortium. European Journal of Neurology, 2022, 29, 2355-2366.	1.7	3
16	Confirmed disability progression as a marker of permanent disability in multiple sclerosis. European Journal of Neurology, 2022, , .	1.7	1
17	Eventâ€based modeling in temporal lobe epilepsy demonstrates progressive atrophy from crossâ€sectional data. Epilepsia, 2022, 63, 2081-2095.	2.6	11
18	Longitudinal maturation of resting state networks: Relevance to sustained attention and attention deficit/hyperactivity disorder. Cognitive, Affective and Behavioral Neuroscience, 2022, 22, 1432-1446.	1.0	3

#	Article	IF	CITATIONS
19	Head Motion During MRI Predicted by out-of-Scanner Sustained Attention Performance in Attention-Deficit/Hyperactivity Disorder. Journal of Attention Disorders, 2021, 25, 1429-1440.	1.5	9
20	The histopathological staging of tau, but not amyloid, corresponds to antemortem cognitive status, dementia stage, functional abilities and neuropsychiatric symptoms. International Journal of Neuroscience, 2021, 131, 800-809.	0.8	14
21	Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 755-766.	1.4	11
22	Burnout and psychological distress amongst Australian healthcare workers during the COVID-19 pandemic. Australasian Psychiatry, 2021, 29, 26-30.	0.4	145
23	Cognitive profiles in patients with epileptic and nonepileptic seizures evaluated using a brief cognitive assessment tool. Epilepsy and Behavior, 2021, 115, 107643.	0.9	4
24	Virtual Histology of Cortical Thickness and Shared Neurobiology in 6 Psychiatric Disorders. JAMA Psychiatry, 2021, 78, 47.	6.0	136
25	Determinants of therapeutic lag in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1838-1851.	1.4	3
26	Adverse events related to antiepileptic drugs. Epilepsy and Behavior, 2021, 115, 107657.	0.9	7
27	Assessment of the DTIâ€ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. Journal of Neuroimaging, 2021, 31, 569-578.	1.0	68
28	Prenatal valproate exposure and adverse neurodevelopmental outcomes: Does sex matter?. Epilepsia, 2021, 62, 709-719.	2.6	6
29	Clinical predictors of discordance between screening tests and psychiatric assessment for depressive and anxiety disorders among patients being evaluated for seizure disorders. Epilepsia, 2021, 62, 1170-1183.	2.6	14
30	Characterizing neuroanatomic heterogeneity in people with and without ADHD based on subcortical brain volumes. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1140-1149.	3.1	14
31	Odor Identification Testing Can Assist in the Clinical Distinction Between Psychiatric Disorders and Neurological/Neurodegenerative Disorders. Alzheimer Disease and Associated Disorders, 2021, 35, 244-249.	0.6	1
32	Evolution of Brain Volume Loss Rates in Early Stages of Multiple Sclerosis. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	15
33	Analysis of structural brain asymmetries in attentionâ€deficit/hyperactivity disorder in 39 datasets. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2021, 62, 1202-1219.	3.1	40
34	Psychiatric symptoms are the strongest predictors of quality of life in patients with drug-resistant epilepsy or psychogenic nonepileptic seizures. Epilepsy and Behavior, 2021, 117, 107861.	0.9	14
35	Lesserâ€Known Aspects of Deep Brain Stimulation for Parkinson's Disease: Programming Sessions, Hardware Surgeries, Residential Care Admissions, and Deaths. Neuromodulation, 2021, , .	0.4	2
36	Effects of High- and Low-Efficacy Therapy in Secondary Progressive Multiple Sclerosis. Neurology, 2021, 97, e869-e880.	1.5	15

#	Article	IF	CITATIONS
37	Utilization of Multiple Sclerosis Therapies in the Middle East Over a Decade: 2009–2018. CNS Drugs, 2021, 35, 1097-1106.	2.7	7
38	Cognition and psychopathology in autoimmune encephalitides: A focus on risk factors and patient outcomes. Clinical and Experimental Neuroimmunology, 2021, 12, 182-191.	0.5	3
39	Association Between Psychiatric Comorbidities and Mortality in Epilepsy. Neurology: Clinical Practice, 2021, 11, 429-437.	0.8	7
40	Psychiatric and cognitive characteristics of older adults admitted to a Video-EEG monitoring (VEM) unit. Epilepsy and Behavior, 2021, 120, 107987.	0.9	1
41	072â€Impact of telehealth on multiple sclerosis (MS) outpatient clinics during the COVID-19 pandemic. , 2021, , .		0
42	006â€Comparison of multiple disease modifying therapies in multiple sclerosis with marginal structural models. , 2021, , .		0
43	008â€Disease reactivation after cessation of disease-modifying therapy in relapsing-remitting multiple sclerosis. , 2021, , .		1
44	Intraoperative magnetic resonance imaging in epilepsy surgery: A systematic review and meta-analysis. Journal of Clinical Neuroscience, 2021, 91, 1-8.	0.8	4
45	Low prevalence of amyloid and tau pathology in drugâ€resistant temporal lobe epilepsy. Epilepsia, 2021, 62, 3058-3067.	2.6	8
46	The effect of improved dietary control on cognitive and psychiatric functioning in adults with phenylketonuria: the ReDAPT study. Orphanet Journal of Rare Diseases, 2021, 16, 35.	1.2	18
47	Effect of Disease-Modifying Therapy on Disability in Relapsing-Remitting Multiple Sclerosis Over 15 Years. Neurology, 2021, 96, e783-e797.	1.5	54
48	Prefrontal and frontostriatal structures mediate academic outcomes associated with ADHD symptoms. Brain Disorders, 2021, 4, 100023.	1.1	1
49	404 - Factors associated with diagnostic delay in younger-onset dementia iagnostic delay in younger-onset dementia. International Psychogeriatrics, 2021, 33, 31-31.	0.6	0
50	Psychiatric symptoms are the strongest predictors of quality of life in patients with drug-resistant epilepsy or psychogenic nonepileptic seizures: Authors' response. Epilepsy and Behavior, 2021, , 108436.	0.9	0
51	Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial. BMJ Open, 2021, 11, e055019.	0.8	4
52	Sodium selenate as a disease-modifying treatment for mild–moderate Alzheimer's disease: an open-label extension study. BMJ Neurology Open, 2021, 3, e000223.	0.7	7
53	A phase 1b open label study of sodium selenate as a diseaseâ€modifying treatment for behavioural variant frontoâ€ŧemporal dementia. Alzheimer's and Dementia, 2021, 17, .	0.4	0
54	The diagnostic challenge among young onset dementia syndromes and primary psychiatric diseases: Results of a retrospective, 20â€year crossâ€sectional study. Alzheimer's and Dementia, 2021, 17, .	0.4	0

#	Article	IF	CITATIONS
55	Resting-state functional connectivity, cognition, and fatigue in response to cognitive exertion: a novel study in adolescents with chronic fatigue syndrome. Brain Imaging and Behavior, 2020, 14, 1815-1830.	1.1	18
56	A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A â€~C-reactive protein' for psychiatrists and neurologists?. Australian and New Zealand Journal of Psychiatry, 2020, 54, 57-67.	1.3	40
57	Psychometric properties of the Hospital Anxiety and Depression Scale in an inpatient video-monitoring epilepsy cohort. Epilepsy and Behavior, 2020, 103, 106631.	0.9	5
58	Clinical and therapeutic predictors of disease outcomes in AQP4-IgC+ neuromyelitis optica spectrum disorder. Multiple Sclerosis and Related Disorders, 2020, 38, 101868.	0.9	29
59	Longitudinal patterns of white matter fibre density and morphology in children are associated with age and pubertal stage. Developmental Cognitive Neuroscience, 2020, 45, 100853.	1.9	24
60	Treatment response score to glatiramer acetate or interferon beta-1a. Neurology, 2020, 96, 10.1212/WNL.0000000000010991.	1.5	6
61	Development and validation of a screening questionnaire for psychogenic nonepileptic seizures. Epilepsy and Behavior, 2020, 112, 107482.	0.9	9
62	A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia. BMJ Open, 2020, 10, e040100.	0.8	11
63	Reply: Aggressive multiple sclerosis: a matter of measurement and timing. Brain, 2020, 143, e98-e98.	3.7	Ο
64	Mortality in patients with psychogenic nonepileptic seizures. Neurology, 2020, 95, e643-e652.	1.5	75
65	Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis. JAMA Neurology, 2020, 77, 1398.	4.5	21
66	Delay from treatment start to full effect of immunotherapies for multiple sclerosis. Brain, 2020, 143, 2742-2756.	3.7	24
67	Serum microRNA is a biomarker for post-operative monitoring in glioma. Journal of Neuro-Oncology, 2020, 149, 391-400.	1.4	27
68	Longitudinal Trajectories of Sustained Attention Development in Children and Adolescents with ADHD. Journal of Abnormal Child Psychology, 2020, 48, 1529-1542.	3.5	18
69	A phase 1B open″abelled study of sodium selenate as a disease modifying treatment for possible behavioural variant frontoâ€ŧemporal dementia. Alzheimer's and Dementia, 2020, 16, e039192.	0.4	1
70	Neurofilament light chain in psychiatric and neurodegenerative disorders: A â€~câ€reactive protein' for the brain?. Alzheimer's and Dementia, 2020, 16, e041347.	0.4	1
71	Sniffin' Sticks Screening 12 Test can assist in the clinical distinction between psychiatric disorders and neurological/neurodegenerative disorders. Alzheimer's and Dementia, 2020, 16, e042482.	0.4	0
72	Factors associated with subjective cognitive function in epilepsy and psychogenic non-epileptic seizures. Epilepsy Research, 2020, 163, 106342.	0.8	9

#	Article	IF	CITATIONS
73	Early clinical markers of aggressive multiple sclerosis. Brain, 2020, 143, 1400-1413.	3.7	32
74	Subcortical Brain Volume, Regional Cortical Thickness, and Cortical Surface Area Across Disorders: Findings From the ENIGMA ADHD, ASD, and OCD Working Groups. American Journal of Psychiatry, 2020, 177, 834-843.	4.0	120
75	Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study. Lancet Neurology, The, 2020, 19, 307-316.	4.9	219
76	Antiepileptic drugs are not independently associated with cognitive dysfunction. Neurology, 2020, 94, e1051-e1061.	1.5	34
77	The neuropsychological spectrum of anti-LGI1 antibody mediated autoimmune encephalitis. Journal of Neuroimmunology, 2020, 345, 577271.	1.1	23
78	Personality profiles differ between patients with epileptic seizures and patients with psychogenic non-epileptic seizures. Seizure: the Journal of the British Epilepsy Association, 2019, 73, 1-8.	0.9	12
79	Abbreviated assessment of psychopathology in patients with suspected seizure disorders. Epilepsy and Behavior, 2019, 100, 106530.	0.9	3
80	A network analysis approach to ADHD symptoms: More than the sum of its parts. PLoS ONE, 2019, 14, e0211053.	1.1	32
81	Brain Imaging of the Cortex in ADHD: A Coordinated Analysis of Large-Scale Clinical and Population-Based Samples. American Journal of Psychiatry, 2019, 176, 531-542.	4.0	261
82	002â€Therapeutic lag in relapsing multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, A1.2-A1.	0.9	1
83	PACS Integration of Semiautomated Imaging Software Improves Day-to-Day MS Disease Activity Detection. American Journal of Neuroradiology, 2019, 40, 1624-1629.	1.2	3
84	Optic Radiation Tractography in Pediatric Brain Surgery Applications: A Reliability and Agreement Assessment of the Tractography Method. Frontiers in Neuroscience, 2019, 13, 1254.	1.4	9
85	Distinct psychopathology profiles in patients with epileptic seizures compared to non-epileptic psychogenic seizures. Epilepsy Research, 2019, 158, 106234.	0.8	15
86	Supranutritional Sodium Selenate Supplementation Delivers Selenium to the Central Nervous System: Results from a Randomized Controlled Pilot Trial in Alzheimer's Disease. Neurotherapeutics, 2019, 16, 192-202.	2.1	69
87	Multimodal Structural Neuroimaging Markers of Brain Development and ADHD Symptoms. American Journal of Psychiatry, 2019, 176, 57-66.	4.0	30
88	Metabolic patterns and seizure outcomes following anterior temporal lobectomy. Annals of Neurology, 2019, 85, 241-250.	2.8	25
89	Age, sex, and puberty related development of the corpus callosum: a multi-technique diffusion MRI study. Brain Structure and Function, 2018, 223, 2753-2765.	1.2	50
90	Different brain networks underlying intelligence in autism spectrum disorders. Human Brain Mapping, 2018, 39, 3253-3262.	1.9	26

#	Article	IF	CITATIONS
91	Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type. Journal of Alzheimer's Disease, 2018, 62, 417-427.	1.2	5
92	Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E5154-E5163.	3.3	299
93	Development of white matter fibre density and morphology over childhood: A longitudinal fixel-based analysis. NeuroImage, 2018, 183, 666-676.	2.1	66
94	Neurite density index is sensitive to age related differences in the developing brain. NeuroImage, 2017, 148, 373-380.	2.1	101
95	White matter alterations at pubertal onset. NeuroImage, 2017, 156, 286-292.	2.1	47
96	The effect of single-dose methylphenidate on resting-state network functional connectivity in ADHD. Brain Imaging and Behavior, 2017, 11, 1422-1431.	1.1	29
97	Shortâ€ŧerm white matter alterations in Alzheimer's disease characterized by diffusion tensor imaging. Journal of Magnetic Resonance Imaging, 2016, 43, 627-634.	1.9	11
98	A Phase IIa Randomized Control Trial ofÂVEL015 (Sodium Selenate) inÂMild-Moderate Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 54, 223-232.	1.2	53
99	Cortical morphometry in attention deficit/hyperactivity disorder: Contribution of thickness and surface area to volume. Cortex, 2016, 82, 1-10.	1.1	41
100	Differential Functional Connectivity Correlates of Cerebrospinal Fluid Biomarkers in Dementia of the Alzheimer's Type. Neurodegenerative Diseases, 2016, 16, 147-151.	0.8	11
101	Structural neuroimaging correlates of cognitive status in older adults: A person-oriented approach. Journal of Clinical Neuroscience, 2016, 30, 77-82.	0.8	4
102	Developmental brain trajectories in children with ADHD and controls: a longitudinal neuroimaging study. BMC Psychiatry, 2016, 16, 59.	1.1	54
103	MRI correlates of general intelligence in neurotypical adults. Journal of Clinical Neuroscience, 2016, 24, 128-134.	0.8	45
104	Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2015, 47, 965-975.	1.2	18
105	Longitudinal Partial Volume Correction in 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Studies of Alzheimer Disease. Journal of Computer Assisted Tomography, 2015, 39, 559-564.	0.5	4
106	Abstract T P75: Vertex Analysis Demonstrates Significant Changes in Contralesional Thalamus 3 Months After Ischemic Stroke. Stroke, 2015, 46, .	1.0	0
107	O2-03-04: MR DIFFUSION IMAGING AND PHYSICAL ACTIVITY IN PEOPLE AT RISK OF ALZHEIMER'S DISEASE. , 2014, 10, P168-P169.		0